RESUMEN
A 71-year-old female with relapsed IgA lambda myeloma developed progressive cytopenia. The peripheral blood film showed 5% blastoid cells. Flow cytometry analysis was indicative of plasma cells. The bone marrow smear was packed with plasmablasts. Target CD138-cell FISH and molecular karyotyping identified a complex genome. NGS identified high-risk mutations. Bone marrow histology confirmed myeloma with no evidence of acute leukaemia. The patient was diagnosed with plasmablastic progression of myeloma and secondary PCL. Secondary PCL patients have a poor prognosis. It is essential to recognize this subtype and explore a novel treatment approach.
Asunto(s)
Leucemia de Células Plasmáticas , Células Plasmáticas , Humanos , Femenino , Anciano , Leucemia de Células Plasmáticas/patología , Leucemia de Células Plasmáticas/genética , Leucemia de Células Plasmáticas/diagnóstico , Células Plasmáticas/patología , Mieloma Múltiple/patología , Mieloma Múltiple/diagnóstico , MutaciónRESUMEN
ABSTRACT: Angioimmunoblastic T-cell lymphoma (AITL), a subtype of peripheral T-cell lymphoma (PTCL), is associated with unique clinical, morphological, and immunohistochemical features. The peripheral circulation might show presence of an occasional reactive plasma cell but significant plasmacytosis masquerading as plasma cell leukemia is rare. We report a case of AITL in a 42-year-old male, who presented with two-month history of generalized lymphadenopathy. On investigations, he had hypergammaglobulinemia and plasmacytosis in the peripheral blood and bone marrow masquerading as plasma cell leukemia. Immunohistochemistry and serum protein electrophoresis revealed polyclonal nature of plasma cells. Diagnosis of AITL was made on cervical lymph node biopsy. This case highlights the diagnostic challenge faced due to heterogeneity in the clinical presentation and pathological findings and to alert the clinician so that timely accurate diagnosis can be made to initiate the treatment.
Asunto(s)
Médula Ósea , Inmunohistoquímica , Ganglios Linfáticos , Linfoma de Células T Periférico , Células Plasmáticas , Humanos , Masculino , Adulto , Médula Ósea/patología , Células Plasmáticas/patología , Ganglios Linfáticos/patología , Linfoma de Células T Periférico/diagnóstico , Linfoma de Células T Periférico/patología , Diagnóstico Diferencial , Biopsia , Linfadenopatía Inmunoblástica/diagnóstico , Linfadenopatía Inmunoblástica/patología , Hipergammaglobulinemia/diagnóstico , Linfadenopatía/patología , Linfadenopatía/diagnóstico , Leucemia de Células Plasmáticas/diagnóstico , Leucemia de Células Plasmáticas/patologíaRESUMEN
BACKGROUND: The aim of the study was to investigate the clinical and laboratory characteristics of IgM primary plasma cell leukemia. METHODS: We retrospectively analyzed a case of clinical and laboratory characteristics of IgM primary plasma cell leukemia and review related literature of patient with primary plasma cell leukemia. RESULTS: Laboratory tests: Alanine aminotransferase 128 U/L, Aspartate aminotransferase 245 U/L, Globulin 47.8 g/L, Lactate dehydrogenase 1,114 U/L, Creatinine 111.7 mol/L, Serum calcium 2.47 mmol/L, ß2 microglobulin 8.52 µg/mL, Immunoglobulin G 31.41 g/L, D-dimer 2.34 mg/L, Prothrombin time 13.6 seconds Fibrinogen 2 g/L, White blood cell 7.38 x 109/L, Red blood cell 3.46 x 1012/L, Hemoglobin 115 g/L, Platelet 7 x 109/L, and 12% Primitive naive cells can be seen in peripheral blood smear. Bone marrow smear: Accounted for 52% of original cells, the cell size, shape is irregular, the edge is not neat, the cell quality is rich, stained gray blue, cytoplasmic staining uneven, some devouring blood cells can be seen in the cytoplasm or unknown substance, the nucleus shape is irregular, visible distortion and fold, is visible on the part of the nuclei cavitation sample inclusions, chromatin is meticulous, partly visible large nucleoli. Flow cytometry results showed abnormal cell group held 23.85% of nuclear cells, expression of CD38, CD138, CD117, cKappa, partly CD20, weak expressing CD45, not express CD27, CD19, CD56, CD200, CD81, cLambda. It was a monoclonal plasma cell with an abnormal phenotype, consistent with a plasma cell tumor. Immunofixation electrophoresis results showed that the serum M protein was 22.80 g/L, which was IgG-κ type, the serum free KAP light chain was 232.69 mg/L, the serum free LAM light chain was 5.37 mg/L, and the rFLC (κ-FLC: λFLC) was 43.33. The diagnosis was primary plasmacytic leukemia of light chain type. CONCLUSIONS: Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy. Laboratory staff should pay more attention to and recognize the pleomorphic morphology of neoplastic plasma cells, which can enable timely clinical development of bone marrow smear, biopsy, flow cytometry, and cytogenetic tests providing help in early diagnosis and treatment.
Asunto(s)
Leucemia de Células Plasmáticas , Neoplasias de Células Plasmáticas , Humanos , Leucemia de Células Plasmáticas/diagnóstico , Leucemia de Células Plasmáticas/genética , Leucemia de Células Plasmáticas/patología , Estudios Retrospectivos , Antígenos CD19 , Inmunoglobulina MRESUMEN
Peripheral blood smear (A) demonstrates increased numbers of plasma cells (representative cells indicated by arrows), (B) demonstrates polytypic nature of plasma cells.
Asunto(s)
Linfadenopatía Inmunoblástica , Leucemia de Células Plasmáticas , Linfoma de Células T Periférico , Linfoma de Células T , Humanos , Leucemia de Células Plasmáticas/patología , Linfadenopatía Inmunoblástica/patología , Células Plasmáticas/patología , Linfoma de Células T/patología , Linfoma de Células T Periférico/patologíaRESUMEN
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Careful evaluation of peripheral blood for the presence of circulating plasma cells by morphologic assessment or by flow cytometric analysis is an essential component of the diagnostic workup in all patients with newly diagnosed multiple myeloma (MM) to timely differentiate between MM and primary plasma cell leukemia (pPCL), which is the most aggressive plasma cell dyscrasia. The improvement in survival over time is more modest in pPCL, compared with what has been achieved in MM. pPCL is currently defined by the presence of ≥ 5% circulating plasma cells. However, this cutoff is now challenged by new data, from three large cohorts of patients with newly diagnosed MM, showing that a threshold of 2% circulating tumor cells (CTCs) by flow cytometry can be used to identify a subset of patients with ultra-high-risk MM with comparable prognosis as patients with pPCL. These patients may benefit from more intensified first-line therapies, or from enrollment into specific clinical trials, designed for ultra-high-risk MM and pPCL. Apart from differentiating MM from pPCL, the quantification of CTCs is also useful for risk stratification in MM. The detection of CTCs above a threshold of 0.01%-0.07% (much lower than the threshold to define pPCL) appears to be an independent predictor of poor clinical outcomes in newly diagnosed MM. Additional studies, including transplant-ineligible patients or with incorporation of novel immunotherapies, are needed to identify a definitive prognostic CTC cutoff. The next step will be the incorporation of CTC detection into existing staging systems to improve risk stratification and treatment personalization.
Asunto(s)
Leucemia de Células Plasmáticas , Mieloma Múltiple , Células Neoplásicas Circulantes , Humanos , Leucemia de Células Plasmáticas/diagnóstico , Leucemia de Células Plasmáticas/patología , Leucemia de Células Plasmáticas/terapia , Pronóstico , LinfocitosAsunto(s)
Leucemia Linfoide/sangre , Leucemia Linfoide/diagnóstico , Leucemia de Células Plasmáticas/sangre , Leucemia de Células Plasmáticas/diagnóstico , Diagnóstico Diferencial , Humanos , Leucemia Linfoide/patología , Leucemia de Células Plasmáticas/patología , Masculino , Persona de Mediana EdadRESUMEN
Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
Asunto(s)
Leucemia de Células Plasmáticas/diagnóstico , Células Plasmáticas/patología , Anciano , Femenino , Humanos , Leucemia de Células Plasmáticas/patología , Masculino , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/patología , Pronóstico , Estudios RetrospectivosAsunto(s)
Leucemia de Células Plasmáticas/patología , Trasplante de Pulmón , Trastornos Linfoproliferativos/patología , Anciano , Humanos , Leucemia de Células Plasmáticas/etiología , Trasplante de Pulmón/efectos adversos , Trastornos Linfoproliferativos/etiología , Masculino , Neoplasias de Células Plasmáticas/etiología , Neoplasias de Células Plasmáticas/patología , Células Plasmáticas/patologíaRESUMEN
BACKGROUND: Patients with advanced/aggressive multiple myeloma have limited treatment options to achieve rapid disease control. In eligible patients, bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide is often used. However, many patients are refractory to or have toxicities from bortezomib and there is a need for bridging therapy. We have used a modified regimen incorporating the second-generation proteasome inhibitor carfilzomib (carfilzomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide [KD-PACE]) instead of bortezomib for relapsed/refractory multiple myeloma. PATIENTS AND METHODS: This 2-center retrospective study included consecutive patients receiving KD-PACE for relapsed or refractory multiple myeloma, plasma cell leukemia, or extramedullary myeloma. The primary outcome was the feasibility of KD-PACE as a bridging therapy to a more definitive treatment option. RESULTS: Fifty-two patients were included. The median age was 57 years, and 67% were male. Thirty-one patients were bridged with KD-PACE to autologous hematopoietic stem cell transplant (29%), allogenic hematopoietic stem cell transplant (27%), or a clinical trial (12%). Patients bridged to autologous hematopoietic stem cell transplant, allogenic hematopoietic stem cell transplant, or a clinical trial had a superior progression-free survival (8.3 months vs 2.3 months in the nonbridged group; P < .001) and overall survival (median, 16.7 months vs 4.3 months in the nonbridged group; P < .001). No unexpected toxicities occurred from the treatment regimen. CONCLUSION: KD-PACE is a promising treatment option for select patients with advanced/aggressive forms of myeloma requiring rapid disease control before a more definitive salvage therapy such as auto/allotransplantation or a clinical trial.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Mieloma Múltiple/tratamiento farmacológico , Terapia Recuperativa , Anciano , Femenino , Trasplante de Células Madre Hematopoyéticas , Humanos , Leucemia de Células Plasmáticas/tratamiento farmacológico , Leucemia de Células Plasmáticas/patología , Leucemia de Células Plasmáticas/cirugía , Masculino , Persona de Mediana Edad , Mieloma Múltiple/patología , Mieloma Múltiple/cirugía , Oligopéptidos/uso terapéutico , Inhibidores de Proteasoma/uso terapéutico , Recurrencia , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
BACKGROUND: Secondary plasma cell leukaemia (sPCL) is an aggressive form of multiple myeloma (MM), but the mechanism underlying MM progresses into PCL remains unknown. METHODS: Gene expression profiling of MM patients and PCL patients was analysed to identify the molecular differences between the two diseases. Cox survival regression and Kaplan-Meier analysis were performed to illustrate the impact of integrin subunit alpha 6 (ITGA6) on prognosis of MM. Invasion assays were performed to assess whether ITGA6 regulated the progression of MM to PCL. RESULTS: Gene expression profiling analyses showed that cell metastasis pathways were enriched in PCL and ITGA6 was differentially expressed between PCL and MM. ITGA6 expression was an independent prognostic factor for event-free survival (EFS) and overall survival (OS) of MM patients. Moreover, the stratification ability of the International Staging System (ISS) of MM was improved when including ITGA6 expression. Functional studies uncovered that increased ITGA6 reduced the myeloma cell invasion. Additionally, low expression of ITGA6 resulted from epigenetic downregulating of its anti-sense non-coding RNA, ITGA6-AS1. CONCLUSION: Our data reveal that ITGA6 gradually decreases during plasma cell dyscrasias progression and low expression of ITGA6 contributes to myeloma metastasis. Moreover, ITGA6 abundance might help develop MM prognostic stratification.
Asunto(s)
Integrina alfa6/genética , Leucemia de Células Plasmáticas/genética , Mieloma Múltiple/genética , Biomarcadores de Tumor/genética , Línea Celular Tumoral , Proliferación Celular/genética , Progresión de la Enfermedad , Regulación hacia Abajo/genética , Regulación hacia Abajo/fisiología , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Humanos , Integrina alfa6/fisiología , Leucemia de Células Plasmáticas/diagnóstico , Leucemia de Células Plasmáticas/mortalidad , Leucemia de Células Plasmáticas/patología , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/mortalidad , Mieloma Múltiple/patología , PronósticoAsunto(s)
Núcleo Celular , Leucemia de Células Plasmáticas , Linfocitos , Núcleo Celular/metabolismo , Núcleo Celular/patología , Humanos , Leucemia de Células Plasmáticas/metabolismo , Leucemia de Células Plasmáticas/patología , Linfocitos/metabolismo , Linfocitos/patología , Masculino , Persona de Mediana EdadRESUMEN
Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with a guarded prognosis. The diagnosis is confirmed when peripheral blood plasma cells (PCs) exceed 20% of white blood cells or 2000/µL. Emerging data demonstrates that patients with lower levels of circulating (PCs) have the same adverse prognosis, challenging the clinical disease definition, but supporting the adverse impact of circulating PCs. The cornerstone of treatment consists of combination therapy incorporating a proteasome inhibitor, an immunomodulatory agent, steroids, and/or anthracyclines and alkylators as part of more-intensive chemotherapy, followed by consolidative autologous hematopoietic cell transplantation in eligible patients and then maintenance therapy. Monoclonal antibodies are also currently being evaluated in this setting with a strong rationale for their use based on their activity in multiple myeloma (MM). Due to limited therapeutic studies specifically evaluating pPCL, patients with pPCL should be considered for clinical trials. In contrast to MM, the outcomes of patients with pPCL have only modestly improved with novel therapies, and secondary PCL arising from MM in particular is associated with a dismal outlook. Newer drug combinations, immunotherapy, and cellular therapy are under investigation, and these approaches hopefully will demonstrate efficacy to improve the prognosis of pPCL.
Asunto(s)
Leucemia de Células Plasmáticas/diagnóstico , Leucemia de Células Plasmáticas/terapia , Animales , Antineoplásicos/uso terapéutico , Manejo de la Enfermedad , Trasplante de Células Madre Hematopoyéticas , Humanos , Quimioterapia de Inducción , Leucemia de Células Plasmáticas/patología , Quimioterapia de Mantención , Cuidados Paliativos , PronósticoRESUMEN
A 70-year-old man with medical history of IgG kappa multiple myeloma, initially diagnosed in 2017, underwent induction therapy with carfilzomib, lenalidomide and dexamethasone followed by autologous haematopoietic stem cell transplantation. Nine months following transplant, disease relapsed in the form of plasma cell leukaemia. Fluorescent in situ hybridisation of malignant plasma cells revealed t(11;14). A combination therapy including venetoclax was used based on efficacy data for Bcl-2 inhibitor venetoclax from available early-phase clinical trials in patients with relapsed multiple myeloma with t(11;14) and other published case studies. Unfortunately, the disease was primary refractory, and after further ineffective therapies, the patient did not have a successful outcome.
Asunto(s)
Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Trasplante de Células Madre Hematopoyéticas , Leucemia de Células Plasmáticas/tratamiento farmacológico , Mieloma Múltiple/terapia , Recurrencia Local de Neoplasia/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Anciano , Dexametasona/administración & dosificación , Humanos , Hibridación Fluorescente in Situ , Lenalidomida/administración & dosificación , Leucemia de Células Plasmáticas/diagnóstico por imagen , Leucemia de Células Plasmáticas/genética , Leucemia de Células Plasmáticas/patología , Masculino , Recurrencia Local de Neoplasia/diagnóstico por imagen , Recurrencia Local de Neoplasia/genética , Recurrencia Local de Neoplasia/patología , Oligopéptidos/administración & dosificación , Proteínas de Fusión Oncogénica , Translocación Genética , Trasplante Autólogo , Insuficiencia del TratamientoAsunto(s)
Leucemia de Células Plasmáticas/patología , Anciano , Antígenos CD/análisis , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Femenino , Humanos , Leucemia de Células Plasmáticas/líquido cefalorraquídeo , Leucemia de Células Plasmáticas/terapia , Células Plasmáticas/patología , Trasplante de Células MadreRESUMEN
Plasma cell leukemia represents the most aggressive form of plasma cell dyscrasia. We report a 67-year old male with no previous medical illnesses presented with anemic symptoms. Blood film revealed 35% circulating plasma cells, bone marrow biopsy showed plasma cells constituting 85%. Diagnosis of primary plasma cell leukemia was completed. Induction chemotherapy with bortezomib, doxorubicin, and dexamethasone was started. After the first cycle, plasma cells in peripheral blood disappeared. The patient had complete remission at evaluation after the third cycle. Re-evaluation after the sixth cycle showed that he maintained remission. As he was non-transplant eligible, he was we kept on maintenance bortezomib. Twenty-four months after the diagnosis, the patient remains in remission.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Leucemia de Células Plasmáticas/tratamiento farmacológico , Anciano , Bortezomib/administración & dosificación , Dexametasona/administración & dosificación , Doxorrubicina/administración & dosificación , Estudios de Seguimiento , Humanos , Leucemia de Células Plasmáticas/diagnóstico , Leucemia de Células Plasmáticas/patología , Masculino , Inducción de RemisiónAsunto(s)
Leucemia de Células Plasmáticas , Imagen por Resonancia Magnética , Síndrome de Pancoast , Tomografía Computarizada por Rayos X , Diagnóstico Diferencial , Humanos , Leucemia de Células Plasmáticas/diagnóstico por imagen , Leucemia de Células Plasmáticas/metabolismo , Leucemia de Células Plasmáticas/patología , Masculino , Persona de Mediana Edad , Síndrome de Pancoast/diagnóstico por imagen , Síndrome de Pancoast/metabolismo , Síndrome de Pancoast/patologíaRESUMEN
Plasma cell leukaemia (PCL) is an aggressive haematological malignancy which is classified into primary (pPCL) and secondary PCL. A 39-year-old Indian man presented to the Department of Hematology with a 2-week history of fever and lethargy. Clinically, he was pale and febrile. Haemogram revealed bicytopenia with leucocytosis. The peripheral blood film portrayed rouleax formation with 45% of circulating plasma cells. Serum protein electrophoresis and immunofixation revealed IgG lambda paraproteinaemia of 48 g/L. Bone marrow aspirate, flow cytometry and trephine were consistent with IgG lambda pPCL. He was treated with six cycles of bortezomib, thalidomide and dexamethasone combination chemotherapy followed by high-dose melphalan conditioning and autologous stem cell transplant. Currently, he is in complete remission for the past 18 months and is on oral lenalidomide maintenance therapy. Prognosis is often dismal in pPCL with the median overall survival below 1 year if treatment is delayed.
Asunto(s)
Leucemia de Células Plasmáticas/diagnóstico , Leucemia de Células Plasmáticas/terapia , Adulto , Antineoplásicos/uso terapéutico , Conservadores de la Densidad Ósea/uso terapéutico , Médula Ósea/patología , Bortezomib/uso terapéutico , Dexametasona/uso terapéutico , Diagnóstico Diferencial , Quimioterapia Combinada/métodos , Humanos , Inmunoglobulina G/análisis , Cadenas lambda de Inmunoglobulina/análisis , Inmunosupresores/uso terapéutico , Leucemia de Células Plasmáticas/patología , Masculino , Talidomida/uso terapéutico , Ácido Zoledrónico/uso terapéuticoRESUMEN
Primary plasma cell leukemia (pPCL) is a rare and aggressive form of multiple myeloma (MM) that is characterized by the presence of ≥20% circulating plasma cells. Overall survival remains poor despite advances of anti-MM therapy. The disease biology as well as molecular mechanisms that distinguish pPCL from non-pPCL MM remain poorly understood and, given the rarity of the disease, are challenging to study. In an attempt to identify key biological mechanisms that result in the aggressive pPCL phenotype, we performed whole-exome sequencing and gene expression analysis in 23 and 41 patients with newly diagnosed pPCL, respectively. The results reveal an enrichment of complex structural changes and high-risk mutational patterns in pPCL that explain, at least in part, the aggressive nature of the disease. In particular, pPCL patients with traditional low-risk features such as translocation t(11;14) or hyperdiploidy accumulated adverse risk genetic events that could account for the poor outcome in this group. Furthermore, gene expression profiling showed upregulation of adverse risk modifiers in pPCL compared to non-pPCL MM, while adhesion molecules and extracellular matrix proteins became increasingly downregulated. In conclusion, this is one of the largest studies to dissect pPCL on a genomic and molecular level.